PREDICT 2.0: Invloed van therapiekeuze op 5-jaarsoverleving bij patiënten met borstkanker
Samengesteld prognostisch instrument bedoeld om patiënten met borstkanker te informeren en om behandelbesluiten over adjuvante, systemische therapie te ondersteunen.
Details Files & References
Composite
Model author
Version
1.9
Revision date
2018-07-23
Specialty
MeSH terms
  • Breast Cancer
  • Chemotherapy
  • Trastuzumab
  • Surgery
  • Hormonal Antineoplastic Drugs
  • Survival
  • Status
    public
    Share

    Related files

    No related files available

    Supporting Publications

    No supporting publications available

    {{ resultSubheader }}

    {{ model.survival.PITTitle }}

    {{ model.survival.YNETitle }}

    Results
    Note
    Notes are only visible in the result download and will not be saved by Evidencio

    Composite model

    Conditional information

    Result interpretation

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Comments
    Rating
    Comment
    Please enter a comment of rating
    Comments are visible to anyone

    Model feedback

    No feedback yet 1 Comment {{ model.comments.length }} Comments
    Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
    Underlying models
    5-jaars overleving borstkanker na uitsluitend chirurgische behandeling (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    5-jaars overleving borstkanker na chirurgie & hormoontherapie (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    5-jaars overleving borstkanker na chirurgie, hormoontherapie & chemotherapie (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    5-jaars overleving borstkanker na chirurgie, chemotherapie, hormoontherapie & trastuzumab (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    Overlevingswinst van adjuvante hormoontherapie (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    Extra overlevingswinst van adjuvante chemotherapie (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD
    Extra overlevingswinst van trastuzumab (PREDICT versie 2.0)
    Research authors: Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD